Our very first MET-FINGER participant has signed up in the UK! What an important and exciting milestone for the MET-FINGER dementia prevention study, aimed at investigating the effects of combined lifestyle interventions, vascular risk monitoring, and the medication metformin.
The MET-FINGER trial invites persons aged 60-79 years who do not have memory problems nor a dementia diagnosis. With the first participant enrolled, the UK branch of the project is now officially kicked off, and ready to recruit a total of 300 participants in the UK. The study will also be conducted in Finland and Sweden, with 200 and 100 participants respectively. It is the first ever dementia trial that looks at a combination of modifiable lifestyle factors, vascular risk factors, and medication.
Building further on the original ground-breaking FINGER study first published in 2015, MET-FINGER is a collaboration between Imperial College London, The Finnish Institute for Health and Welfare (THL), Karolinska University Hospital, and the FINGERS Brain Health Institute, and funded by the Alzheimer’s Drug Discovery Foundation, the Part of the Cloud – Gates Partnership Grant Program at Alzheimer’s Assocation, Alzheimerfonden, and the Swedish governmental funding ALF (through Vetenskapsrådet/The Swedish Research Council).